Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Spengler

Showing results (111-120 of 224) with videos related to

Pageof 23
Sort By:
Journal of Hepatology|March 15, 2005
Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC)Jacob Nattermann, Angelika Maria Schneiders, Ludger Leifeld, et al.
Frontiers in Immunology|August 24, 2019
NK Cells in Ascites From Liver Disease Patients Display a Particular Phenotype and Take Part in Antibacterial Immune ResponsePhilipp Lutz, Hannah C Jeffery, Nicholas Jones, et al.
Journal of Hepatology|May 14, 2013
Impaired CD4⁺ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patientsAndreas Glässner, Marianne Eisenhardt, Pavlos Kokordelis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 29, 2015
CD3(+)CD56(+) Natural Killer-Like T Cells Display Anti-HCV Activity but Are Functionally Impaired in HIV(+) Patients With Acute Hepatitis CPavlos Kokordelis, Benjamin Krämer, Christoph Boesecke, et al.
Infection Control and Hospital Epidemiology|June 27, 2002
Risk of hepatitis C after immunoadsorptionRolf Kaiser, Oliver Geulen, Bertfried Matz, et al.
European Journal of Gastroenterology & Hepatology|August 10, 2002
Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysisKarl August Brensing, Peter Raab, Jochen Textor, et al.
Journal of Gastroenterology|September 14, 2011
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infectionViola Weich, Eva Herrmann, Tje Lin Chung, et al.
BMC Cancer|March 10, 2012
TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patientsChristian Körner, Katarina Riesner, Benjamin Krämer, et al.
World Journal of Hepatology|August 7, 2018
Hepatitis B virus subgenotype F3 reactivation with vaccine escape mutations: A case report and review of the literatureStefan Schlabe, Kathrin van Bremen, Souhaib Aldabbagh, et al.
AIDS (London, England)|August 14, 2013
Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis CBenjamin Krämer, Hans Dieter Nischalke, Christoph Boesecke, et al.
Pageof 23

Showing results (111-120 of 224) with videos related to

Sort By:
Pageof 23
Journal of Hepatology|March 15, 2005
Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC)Jacob Nattermann, Angelika Maria Schneiders, Ludger Leifeld, et al.
Frontiers in Immunology|August 24, 2019
NK Cells in Ascites From Liver Disease Patients Display a Particular Phenotype and Take Part in Antibacterial Immune ResponsePhilipp Lutz, Hannah C Jeffery, Nicholas Jones, et al.
Journal of Hepatology|May 14, 2013
Impaired CD4⁺ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patientsAndreas Glässner, Marianne Eisenhardt, Pavlos Kokordelis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 29, 2015
CD3(+)CD56(+) Natural Killer-Like T Cells Display Anti-HCV Activity but Are Functionally Impaired in HIV(+) Patients With Acute Hepatitis CPavlos Kokordelis, Benjamin Krämer, Christoph Boesecke, et al.
Infection Control and Hospital Epidemiology|June 27, 2002
Risk of hepatitis C after immunoadsorptionRolf Kaiser, Oliver Geulen, Bertfried Matz, et al.
European Journal of Gastroenterology & Hepatology|August 10, 2002
Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysisKarl August Brensing, Peter Raab, Jochen Textor, et al.
Journal of Gastroenterology|September 14, 2011
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infectionViola Weich, Eva Herrmann, Tje Lin Chung, et al.
BMC Cancer|March 10, 2012
TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patientsChristian Körner, Katarina Riesner, Benjamin Krämer, et al.
World Journal of Hepatology|August 7, 2018
Hepatitis B virus subgenotype F3 reactivation with vaccine escape mutations: A case report and review of the literatureStefan Schlabe, Kathrin van Bremen, Souhaib Aldabbagh, et al.
AIDS (London, England)|August 14, 2013
Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis CBenjamin Krämer, Hans Dieter Nischalke, Christoph Boesecke, et al.
Pageof 23